This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1991 Aug;28(2):313-4.

doi: 10.1093/jac/28.2.313.

The penetration of sparfloxacin into human plasma and skin tissues

T Nogita, Y Ishibashi

PMID: 1663927
DOI: 10.1093/jac/28.2.313

The penetration of sparfloxacin into human plasma and skin tissues

T Nogita et al. J Antimicrob Chemother. 1991 Aug.

. 1991 Aug;28(2):313-4.

doi: 10.1093/jac/28.2.313.

Authors

T Nogita, Y Ishibashi

PMID: 1663927
DOI: 10.1093/jac/28.2.313

No abstract available

PubMed Disclaimer

Similar articles

Clinical pharmacokinetics of sparfloxacin.
Shimada J, Nogita T, Ishibashi Y. Shimada J, et al. Clin Pharmacokinet. 1993 Nov;25(5):358-69. doi: 10.2165/00003088-199325050-00002. Clin Pharmacokinet. 1993. PMID: 8287631 Review.
High performance thin-layer chromatographic method for the determination of sparfloxacin in human plasma and its use in pharmacokinetic studies.
Mody VD, Pandya KK, Satia MC, Modi IA, Modi RI, Gandhi TP. Mody VD, et al. J Pharm Biomed Anal. 1998 Apr;16(8):1289-94. doi: 10.1016/s0731-7085(97)00156-8. J Pharm Biomed Anal. 1998. PMID: 9777602
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.
Johnson JH, Cooper MA, Andrews JM, Wise R. Johnson JH, et al. Antimicrob Agents Chemother. 1992 Nov;36(11):2444-6. doi: 10.1128/AAC.36.11.2444. Antimicrob Agents Chemother. 1992. PMID: 1336947 Free PMC article.
Pharmacokinetics of rufloxacin (MF-934) in normal human volunteers after single oral administration.
Mattina R, Bellotti MG, Cocuzza CE, Bonfiglio G. Mattina R, et al. J Chemother. 1989 Jul;1(4 Suppl):574. J Chemother. 1989. PMID: 16312538 No abstract available.
Penetration of temafloxacin into body tissues and fluids.
Sörgel F. Sörgel F. Clin Pharmacokinet. 1992;22 Suppl 1:57-63. doi: 10.2165/00003088-199200221-00010. Clin Pharmacokinet. 1992. PMID: 1319872 Review.

See all similar articles

Cited by

Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.
Barradell LB, Plosker GL, McTavish D. Barradell LB, et al. Drugs. 1993 Aug;46(2):289-312. doi: 10.2165/00003495-199346020-00007. Drugs. 1993. PMID: 7691518 Review.
Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
Fuchs PC, Barry AL, Pfaller MA. Fuchs PC, et al. J Clin Microbiol. 1993 Aug;31(8):2236-7. doi: 10.1128/jcm.31.8.2236-2237.1993. J Clin Microbiol. 1993. PMID: 8396592 Free PMC article.
Clinical pharmacokinetics of sparfloxacin.
Shimada J, Nogita T, Ishibashi Y. Shimada J, et al. Clin Pharmacokinet. 1993 Nov;25(5):358-69. doi: 10.2165/00003088-199325050-00002. Clin Pharmacokinet. 1993. PMID: 8287631 Review.
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Sutton LD, Jones RN. Sutton LD, et al. J Clin Microbiol. 1995 Jan;33(1):146-8. doi: 10.1128/jcm.33.1.146-148.1995. J Clin Microbiol. 1995. PMID: 7699031 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems